Swedish biotechnology company Cantargia AB (STO:CANTA) on Friday reported promising new data from the ongoing CAN10 phase 1 clinical study.
All 68 participants receiving a single dose of CAN10 or placebo showed good safety and encouraging biomarker results.
Notably, a single dose of CAN10 has been shown to effectively block IL-1 and IL-36 signalling in the blood for at least one week, achieving key study endpoints. This strengthens the potential of CAN10's unique mechanism of action for treating autoimmune and inflammatory diseases.
The multi-dose portion of the trial is ongoing.
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Sareum Holdings secures patent allowance for SDC-1801 in China
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Carisma and Moderna expand collaboration
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Merck KGaA initiates Phase III trial for oral cladribine in gMG